Literature DB >> 6824376

Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism.

W V Huval, M A Mathieson, L I Stemp, B M Dunham, A G Jones, D Shepro, H B Hechtman.   

Abstract

The smooth muscle-constricting, platelet amine, serotonin (5-hydroxytryptamine; 5-HT) is theorized to play an important role in the cardiopulmonary dysfunction that accompanies embolization. The present study was designed to examine this hypothesis. Autologous clot, 0.75 g/kg, was injected IV into 14 dogs. After 30 minutes, one half of the animals were randomly assigned to the treatment group and received a bolus infusion of 0.15 mg/kg ketanserin, a quinazoline derivative known to be a selective 5-HT receptor antagonist. Five minutes after embolization there were increases in mean pulmonary arterial pressure (MPAP) from 12 mm to 48 mmHg (p less than 0.001); pulmonary vascular resistance (PVR) from 2.2 mm to 12.2 mmHg X min/L (p less than 0.001); physiologic shunt (QS/QT) from 12% to 44% (p less than 0.01); and physiologic dead space (VD/VT), calculated from end tidal and arterial PCO2, from 8% to 39% (p less than 0.001). Within 15 minutes platelet counts decreased from 186,000/mm3 to 134,800/mm3 (p less than 0.05); 5-HT contained in circulating platelets fell from 1.71 micrograms/ to 1.44 micrograms/10(9) platelets (p less than 0.05). Five minutes after ketanserin, MPAP declined to 27 mmHg and was lower than the control value of 41 mmHg (p less than 0.05); PVR decreased to 6.2 mmHg X min/L, lower than 12 mmHg X min/L in controls (p less than 0.01); QS/QT fell to 26% in contrast to 47% in controls (p less than 0.05); and VD/VT declined moderately to 32% (p less than 0.05), although this value was not different from 38% in control animals. Cardiopulmonary function continued to improve in treated animals until termination of the experiment at four hours when pulmonary angiograms and perfusion scans demonstrated vascular recruitment compared with untreated embolized control dogs. These data demonstrate that the cardiopulmonary consequences of experimental embolization are primarily determined by the vasoconstrictive and bronchoconstrictive actions of 5-HT.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6824376      PMCID: PMC1353113          DOI: 10.1097/00000658-198302000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  18 in total

1.  Quantity, assay and release of serotonin in human platelets.

Authors:  M B ZUCKER; J BORRELLI
Journal:  J Appl Physiol       Date:  1955-01       Impact factor: 3.531

2.  Reflex and direct cardiopulmonary effects of 5-OH-tryptamine (serotonin); their possible role in pulmonary embolism and coronary thrombosis.

Authors:  J H COMROE; B VAN LINGEN; R C STROUD; A RONCORONI
Journal:  Am J Physiol       Date:  1953-06

3.  Reduction of platelet serotonin and the response to pulmonary emboli.

Authors:  C B Rosoff; E W Salzman; V Gurewich
Journal:  Surgery       Date:  1971-07       Impact factor: 3.982

4.  The pulmonary hemodynamic effects of lung thromboemboli in dogs.

Authors:  W C Woolverton; A L Hyman
Journal:  Surgery       Date:  1973-04       Impact factor: 3.982

5.  Circulating negative inotropic agent(s) following pulmonary embolism.

Authors:  T Utsunomiya; M K Krausz; B Dunham; L Levine; D Shepro; H B Hechtman
Journal:  Surgery       Date:  1982-04       Impact factor: 3.982

6.  Platelet and leukocyte lung interactions in patients with respiratory failure.

Authors:  H B Hechtman; E A Lonergan; D Shepro
Journal:  Surgery       Date:  1978-02       Impact factor: 3.982

7.  Prostaglandin control of plasma and platelet 5-hydroxytryptamine in normal and embolized animals.

Authors:  T Utsunomiya; M M Krausz; D Shepro; H B Hechtman
Journal:  Am J Physiol       Date:  1981-11

8.  Effect of histamine, serotonin, and acetylcholine on the peripheral airways.

Authors:  H J Colebatch; C R Olsen; J A Nadel
Journal:  J Appl Physiol       Date:  1966-01       Impact factor: 3.531

9.  Platelet-mediated pulmonary hypertension and hypoxia during pulmonary microembolism: reduction by platelet inhibition.

Authors:  J Mlczoch; A Tucker; E K Weir; J T Reeves; R F Grover
Journal:  Chest       Date:  1978-12       Impact factor: 9.410

10.  Thromboxane mediation of cardiopulmonary effects of embolism.

Authors:  T Utsonomiya; M M Krausz; L Levine; D Shepro; H B Hechtman
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

View more
  8 in total

Review 1.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

2.  Pulmonary embolism: what is known, what remains unsolved?

Authors:  F Lemaire
Journal:  Intensive Care Med       Date:  1984       Impact factor: 17.440

3.  Effect of OKY 046, a thromboxane synthase inhibitor, on lung vascular permeability after pulmonary embolism in sheep.

Authors:  S Lelcuk; J M Klausner; A Merhav; R R Rozin
Journal:  Thorax       Date:  1987-09       Impact factor: 9.139

Review 4.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

5.  Role of serotonin in patients with acute respiratory failure.

Authors:  W V Huval; S Lelcuk; D Shepro; H B Hechtman
Journal:  Ann Surg       Date:  1984-08       Impact factor: 12.969

Review 6.  Gas exchange and pulmonary hypertension following acute pulmonary thromboembolism: has the emperor got some new clothes yet?

Authors:  John Y C Tsang; James C Hogg
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

7.  Aggregating platelets contract isolated canine pulmonary arteries by releasing 5-hydroxytryptamine.

Authors:  M D McGoon; P M Vanhoutte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

Review 8.  Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.

Authors:  F De Clerck; J M van Nueten; R S Reneman
Journal:  Agents Actions       Date:  1984-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.